Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005
- Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005
- This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds
- Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea
- The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term
Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a psychoactive experience, has been gaining popularity recently. It has been lauded as a viable method of treating specific mental health conditions such as depression, anxiety, and attention-deficit/hyperactivity disorder (“ADHD”). However, more research is needed to confirm its safety and efficacy.
One of the main issues that have been highlighted is the substantial medical risk involved with microdosing. Psilocybin, for instance, has shown a binding affinity to the 5-HT2B receptor, which is, in turn, linked to heart valve tissue fibrosis. As such, its consumption, over a long period, could present a patient with cardiovascular health concerns, a legitimate risk that ought to be considered (https://nnw.fm/9TM3m).
In a significant move that remedies the situation, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced its latest drug discovery and its first of many for the new year, MYCO-005. Essentially a novel molecule in its family of psilocin analogs, MYCO-005 has proven to have potentially heart-safe microdose enabling properties while addressing the shortcomings and limitations associated with the first-generation compounds.
“We are very excited about our MYCO-005 family of molecules,” noted Josh Bartch, the Chief Executive Officer (“CEO”) of Mydecine.
“Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market,” he added.
Mydecine’s patent-pending dermal route to administration offers more control over the drug while also potentially eliminating undesirable properties including, but not limited to, nausea. This is achieved by bypassing the digestive system.
Going forward, the company seeks to explore this new feature and study its patent-pending skin permeation technology to produce a low-dosed, time-released patch that does not result in hallucinations for the patient.
“This is one of the many exciting drug discoveries we look forward to sharing in the near term,” noted Mr. Bartch.
This significant milestone for Mydecine proves its commitment to transforming the treatment of mental health and addiction disorders, particularly with psychedelics. It also shows its commitment to research and creating value for its shareholders.
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://nnw.fm/MYCOF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005
- This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds
- Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea
- The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term
Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a psychoactive experience, has been gaining popularity recently. It has been lauded as a viable method of treating specific mental health conditions such as depression, anxiety, and attention-deficit/hyperactivity disorder (“ADHD”). However, more research is needed to confirm its safety and efficacy.
One of the main issues that have been highlighted is the substantial medical risk involved with microdosing. Psilocybin, for instance, has shown a binding affinity to the 5-HT2B receptor, which is, in turn, linked to heart valve tissue fibrosis. As such, its consumption, over a long period, could present a patient with cardiovascular health concerns, a legitimate risk that ought to be considered (https://nnw.fm/9TM3m).
In a significant move that remedies the situation, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced its latest drug discovery and its first of many for the new year, MYCO-005. Essentially a novel molecule in its family of psilocin analogs, MYCO-005 has proven to have potentially heart-safe microdose enabling properties while addressing the shortcomings and limitations associated with the first-generation compounds.
“We are very excited about our MYCO-005 family of molecules,” noted Josh Bartch, the Chief Executive Officer (“CEO”) of Mydecine.
“Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market,” he added.
Mydecine’s patent-pending dermal route to administration offers more control over the drug while also potentially eliminating undesirable properties including, but not limited to, nausea. This is achieved by bypassing the digestive system.
Going forward, the company seeks to explore this new feature and study its patent-pending skin permeation technology to produce a low-dosed, time-released patch that does not result in hallucinations for the patient.
“This is one of the many exciting drug discoveries we look forward to sharing in the near term,” noted Mr. Bartch.
This significant milestone for Mydecine proves its commitment to transforming the treatment of mental health and addiction disorders, particularly with psychedelics. It also shows its commitment to research and creating value for its shareholders.
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://nnw.fm/MYCOF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
